Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy

Health Technology Assessment

Volumn 14, Issue 31, 2010, Pages 1-103

  Saborido, C Martin ^a   Hockenhull, J ^a   Bagust, A ^a   Boland, A ^a   Dickson, R ^a   Todd, D ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; FLECAINIDE ACETATE; PILSICAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TIDIAM LA; UNCLASSIFIED DRUG; WARFARIN;

ADVERSE OUTCOME; AGE DISTRIBUTION; ANGINA PECTORIS; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BLEEDING; BRADYCARDIA; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIDDEN MARKOV MODEL; HOSPITAL CARE; HUMAN; HYPERTENSION; HYPOTENSION; INTERMETHOD COMPARISON; LICENSING; LUNG EDEMA; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHLEBITIS; PRACTICE GUIDELINE; PROBABILITY; QRS COMPLEX; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; REENTRY TACHYCARDIA; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT PLANNING; VALIDATION PROCESS; ATRIAL FIBRILLATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; HOSPITALIZATION; NATIONAL HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; UNITED KINGDOM;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATE MEDICINE;

EID: 77955145717     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14310     Document Type: Review

References (81)

1. Ruigomez A, Johansson S, Wallander MA, Edvardsson N, Garcia Rodriguez LA. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. Int J Cardiol 2009;136:186-92.
2. Levy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns H, et al. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 2003;5:119-22.
3. National Institute for Health and Clinical Excellence. Atrial fibrillation: national clinical guideline for management in primary and secondary care. 2006; updated June 2006. URL: www.nice.org.uk/nicemedia/pdf/cg036fullguideline.pdf.
4. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Disord 2005;5:20.
5. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation. BMC Cardiovasc Disord 2002;2:5.
6. Go A, Hylek E, Philisps K, Chang Y, Henault L, Selby J, et al. Prevalence of diagnosed atrial fibrillatin in adults: national implications for rhythm management and stroke prevention: the ANTicoagulation and Risk Fators in Atrial Fibriallation (ATRIA) Study. JAMA 2001;285: 2370-5.
7. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky J, et al. Characterization of different subsets of atrial fibrillation in generall practice in France: the ALFA study. Circulation 1999;99:3028-35.
8. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
9. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489-96.
10. Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999;84:1029-32.
11. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol 1998;21:2465-9.
12. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recentonset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995;108:355-8.
13. Botto GL, Bonini W, Broffoni T, Espureo M, Cappelletti G, Lombardi R, et al. Randomised, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. Pacing Clin Electrophysiol 1998;21:2480-4.
14. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994;43:305-13.
15. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
16. Capucci A, Villani GQ, Aschieri D, Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Int J Cardiol 1999;68:187-96. [Erratum published in Int J Cardiol 1999;70:213.]
17. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 57 March 2009. London: BMA and RPS; 2009.
18. Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr CR. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007;18: 907-13.
19. Khaykin Y, Wang X, Natale A, Wazni OM, Skanes AC, Humphries KH, et al. Cost comparison of ablation versus antiarrhythmic drugs as firstline therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009;20:7-12.
20. Andrikopoulos G, Tzeis S, Maniadakis N, Mavrakis HE, Vardas PE. Cost-effectiveness of atrial fibrillation catheter ablation. Europace 2009;11: 147-51.
21. Weerasooriya R, Jais P, Le Heuzey JY, Scavee C, Choi KJ, Macle L, et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2003;26:292-4.
22. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recentonset atrial fibrillation with the 'pill-in-the-pocket' approach. N Engl J Med 2004;351:2384-91.
23. Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988;9:634-8.
24. Alp NJ, Bell JA, Shahi M. double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 2000;84:37-40. [Erratum published in Heart 2000;84:331.]
25. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxinquinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995;76:495-8.
26. Kumagai K, Abe H, Hiraki T, Nakashima H, Oginosawa Y, Ikeda H, et al. Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pacing Clin Electrophysiol 2000;23:1880-2.
27. Madonia S, De Simone M, Brai G, Gozzo D, Gristina A, Luciano L, et al. Intravenous versus oral initial load of propafenone for conversion of recentonset atrial fibrillation in the emergency room: a randomised trial. Ital Heart J 2000;1:475-9.
28. Aronow WS. Management of the older person with atrial fibrillation. J Am Ger Soc 1999;47:740-8.
29. Cheng JW, Cheng JWM. Vernakalant in the management of atrial fibrillation. Ann of Pharmacother 2008;42:533-42.
30. Deneer VH, Borgh MB, Kingma JH, Lie AHL, Brouwers JR, Deneer VHM, et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci 2004;26:66-78.
31. Doggrell SA. Amiodarone - waxed and waned and waxed again. Expert Opin Pharmacother 2001;2: 1877-90.
32. Ferreira E, Sunderji R, Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacotherapy 1997;17:1233-7.
33. Follath F, Candinas R, Frielingsdorf J, Follath F, Candinas R, Frielingsdorf J. [Therapy of atrial fibrillation with class III anti-arrhythmia agents]. Herz 1993;18:20-6.
34. Fumeaux T, Cornuz J, Polikar R, Blanc E, Junod A, Kappenberger L, et al. Guidelines for the clinical management of atrial fibrillation: a practical perspective. Swiss Med Wkly 2004;134:235-47.
35. Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation--a review. Can J Cardiol 1997;13:839-42.
36. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-7.
37. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-52.
38. Slavik RS, Zed PJ, Slavik RS, Zed PJ. Intravenous amiodarone for conversion of atrial fibrillation: misled by meta-analysis? Pharmacotherapy 2004;24:792-8.
39. Botto GL, Bonini W, Broffoni T, Molteni S, Lombardi R, Alfieri G, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol 1996;19: 1939-43.
40. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. New Engl J Med 1997;337: 1785-91.
41. Jeantet M, Losay J, Cassinat G, Andral J, Guize L, de Pouvourville G. Paroxysmal atrial fibrillation in community medicine: management intentions and cost estimates. Arch Mal Coeur Vaiss 2001;94: 1103-9.
42. Kerstein J, Soodan A, Qamar M, Majid M, Lichstein E, Hollander G, et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Chest 2004;126:716-24.
43. Lanza LA, Visbal AI, DeValeria PA, Zinsmeister AR, Diehl NN, Trastek VF, et al. Lowdose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection. Ann Thorac Surg 2003;75:223-30.
44. Reddy P, Dunn AB, White CM, Tsikouris JP, Giri S, Kluger J, et al. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. Pharmacotherapy 2002;22:75-80.
45. Reddy P, Kalus JS, Caron MF, Horowitz S, Karapanos A, Coleman CI, et al. Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery. Pharmacotherapy 2004;24:1013-9.
46. Reddy P, Richerson M, Freeman-Bosco L, Dunn A, White CM, Chow MS. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. Am J Health Sys Pharm 1999;56:2211-7.
47. White CM, Caron MF, Kalus JS, Rose H, Song J, Reddy P, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 2003;108(Suppl. 1):II200-6.
48. Zadura M, Grossmann G, Modrzewska A, Klecha T, Klepacka H, Ruminski W. [Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation]. Pol Merkur Lekarski 2001;11:137-9.
49. Zebis LR, Christensen TD, Kristiansen IS, Hjortdal VE, Zebis LR, Christensen TD, et al. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery. Ann Thorac Surg 2008;85:28-32.
50. Bajpai A SI, Camm AJ. Epidemiology and economic burden of atrial fibrillation. US Cardiovascular disease 2007; May 2009. Touch briefings 2007.
51. Chan PS, Vijan S, Morady F, Oral H. Costeffectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006;47:2513-20.
52. McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2008. [Epub ahead of print.]
53. Rodgers MC, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess 2008;12(34).
54. Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10:403-11.
55. Office for National Statistics. Mortality rates. 2008. URL: www.statistics.gov.uk/hub/population/deaths/mortality-rates/index.html.
56. Department of Health. NHS reference costs 2008/09: collection guidance. 2008. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082746.
57. SPAF-Comittee. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998;279:1273-7.
58. Wardlaw JM, Lewis SC, Dennis MS, Counsell C, McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke? Stroke 1998;29:1315-19.
59. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-4.
60. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
61. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomised trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48:2340-7.
62. Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinicallyrelevant bleeding in warfarin-treated patients-- influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009;18: 412-16.
63. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
64. Dorman P, Dennis M, Sandercock P. Are the modified 'simple questions' a valid and reliable measure of health related quality of life after stroke? United Kingdom Collaborators in the International Stroke Trial. J Neurol Neurosurg Psychiatry 2000;69:487-93.
65. Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management. Cardiology 2009;112:270-8.
66. Kaufman ES, Zimmermann PA, Wang T, Dennish GW, 3rd, Barrell PD, Chandler ML, et al. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis. J Am Coll Cardiol 2004;44:1276-82.
67. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-9.
68. Dorian P, Naccarelli GV, Coumel P, Hohnloser SH, Maser MJ. A randomised comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. Am J Cardiol 1996;77:89A-95A.
69. Ara R, Brazier J. Predicting the Short Form- 6D Preference-Based Index Using the Eight Mean Short Form-36 Health Dimension Scores: Estimating Preference-Based Health-Related Utilities When Patient Level Data Are not Available. Value Health 2008. [Epub ahead of print.]
70. McKenna C, Palmer S, Rodgers M, Chambers D, Hawkins N, Golder S, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart 2009;95:542-9.
71. Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing 2009;38:27-32.
72. Rienstra M, Van Gelder IC, Hagens VE, Veeger NJ, Van Veldhuisen DJ, Crijns HJ. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. Eur Heart J 2006;27:357-64.
73. Chambers M, Hutton J, Gladman J. Costeffectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics 1999;16:577-93.
74. Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother 2003;1:53-60.
75. Lamotte M, Annemans L, Bridgewater B, Kendall S, Siebert M. A health economic evaluation of concomitant surgical ablation for atrial fibrillation. Eur J Cardiothorac Surg 2007;32:702-10.
76. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians; 2006.
77. Riley RD, Pritchett EL. Pharmacologic management of atrial fibrillation. J Cardiovasc Electrophysiol 1997;8:818-29.
78. Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980;45:621-6.
79. Gronefeld GC, Hohnloser SH. The 'pill-in-thepocket' approach to atrial fibrillation. N Engl J Med 2005;352:1150-1.
80. Konety SH, Olshansky B. The 'pill-in-the-pocket' approach to atrial fibrillation. N Engl J Med 2005;352:1150-1.
81. Wittkowsky AK. The 'pill-in-the-pocket' approach to atrial fibrillation. N Engl J Med 2005;352:1150-1.